Colchicine CT results
| Phase | Estimate options | Patient groups (placebo/control) | Results | References | |
|---|---|---|---|---|---|
| 4 | Need for artificial ventilation, length of stay in intensive care, and mortality | Ivermectin + colchicine + standard care—45; colchicine + standard care—45; standard care—45 | Colchicine was associated with clinically significant reductions in oxygen demand days, intensive care unit length of stay, and less mortality, while ivermectin added no beneficial effect. | [115] | |
| 2 | Need for artificial lung ventilation, length of stay intensive therapy, mortality | 40/40 | Serum ferritin levels in most patients who received colchicine, returned to normal in contrast to the control group, whose serum ferritin levels remained high. Similarly, the mean CRP and D-dimer values after treatment among participants in the colchicine group were significantly lower than in the control group. Patients in the colchicine group stayed in the hospital for a shorter period compared with the control group. | [116] | |
| 3 | Need for artificial lung ventilation, length of stay in intensive care, mortality | 36/36 | Colchicine reduced the duration of additional oxygen therapy and hospitalization. The drug was well tolerated. Since death was a rare event, one cannot argue that colchicine reduced COVID-19 mortality. | [117] | |
| 3 | CT | Colchicine + standard therapy—89; standard therapy—63 | According to this study, colchicine can improve clinical outcomes and reduce pulmonary infiltration in patients with COVID-19. | [118] | |
| Not studied about | Inflammatory markers, mortality | Colchicine + standard treatment—34; standard treatment—78 | Patients in the colchicine group had lower mortality rates, lower intubation rates, and a higher percentage of discharge. | [119] | |
| Not studied about | Length of hospital stay | Colchicine + standard treatment—165; standard treatment—171 | The average length of hospital stay in the colchicine group was significantly short. | [120] | |